Lessons Learned
GnP, nausea/vomiting, diarrhea, fatigue
ADVERSE EVENTS
Ulixertinib plus gemcitabine and nab-paclitaxel (GnP) had similar grade ≥3 treatment-related adverse events as GnP; however, the triplet regimen is associated with poor overall tolerability, especially fatigue, nausea/vomiting, and diarrhea, leading to patient withdrawal from study.Ulixertinib plus gemcitabine and nab-paclitaxel (GnP) may have at least comparable efficacy as GnP but is complicated by high patient dropouts.Ulixertinib achieved on-target effect by downregulating an intra-tumoral Treatment strategies to overcome adaptive mechanisms to ERK inhibition and with overall better tolerability are needed.